The table here below contains a summary of the main projects
that have passed the laboratory phase and are currently undergoing
development and clinical trials.
Selected Products in development |
| Therapeutic Area |
Drug |
Indication |
Phase |
| Rare / Neglected Diseases |
Eurartesim
(infant formula) 1 |
Uncomplicated malaria |
Early Development |
| Euratesim1^ |
P. vivax malaria |
Early Development |
| STP2062 |
Necrotizing enterocolitis |
Early Development |
| Acetyl-L-Carnitine |
Rett syndrome |
Early Development |
| Acetyl-L-Carnitine |
Fragile X syndrome |
Early Development |
| Acetyl-L-Carnitine |
Leber's optic neuropathy |
Early Development |
| Acetyl-L-Carnitine |
Amyotrophic Lateral Sclerosis |
Early Development |
| Oncaspar10 |
Acute Lymphoblastic Leukemia |
Full Development |
| Artesunate i.v.3 |
Severe malaria |
Full Development |
| Orbec2 |
Graft-Versus-Host Disease |
Full Development |
| Xenbilox® 2 |
Cerebrotendinous Xanthomatosis Disease |
Full Development |
| Cystaran2 |
Cystinosis |
Full Development |
| Defibrotide4 |
Venous Occlusive Disease (VOD) |
Full Development |
| Eurartesim1 |
P. Falcip. malaria |
APPROVED |
| Kalbitor5 |
Hereditary angioedema |
Full Development |
| |
| Therapeutic Area |
Drug |
Indication |
Phase |
| Oncology |
SST00016 |
Various tumors |
Early Development |
| ST1326 |
Cancer metabolism |
Early Development |
| Leuprolide (3m)7 |
Prostate cancer |
Early Development |
| Namitecan^ |
Various tumors |
Early Development |
| Acetyl-L-Carnitine |
Various tumors (combination with cisplatin treatment) |
Full Development |
| Leuprolide (1m)7 |
Prostate cancer |
Full Development |
| |
| Therapeutic Area |
Drug |
Indication |
Phase |
| Immunology & Biotechnology |
DN30 (Anti-Met)8 |
Various tumors |
Early Development |
| Tenatumomab |
NHL (Non-Hodgkin Lymphoma) |
Early Development |
| AvidinOx®^ |
Prostate cancer and other solid tumors |
Early Development |
| AvidinOx® |
Hepatic tumor lesions |
Early Development |
| ST1472 - Thymosin α1^ |
Immunomodulator (aspergillosis) |
Early Development |
| Intraoperative Avidination for Radionuclide Treatment (IART®)^ |
Early breast cancer |
Early Development |
| Propionyl-L-Carnitine |
Ulcerative colitis |
Full Development |
| |
| Therapeutic Area |
Drug |
Indication |
Phase |
| Line extensions and other therapeutica areas |
ST4206^ |
Parkinson's Desease |
Early Development |
| Rostafuroxin9 |
Hypertension |
Early Development |
| Eskim |
Atrial fibrillation |
Full Development |
| Eskim |
Chronic Heart Failure prevention |
Full Development |
| Simvapufa |
Mixed dyslipidemia |
Full Development |
| Simvapufa |
Cardiovascular prevention |
Full Development |
| |
| Therapeutic Area |
Drug |
Indication |
Phase |
| License-out opportunities |
Teglicar^ |
NonInsulin-Dependent Diabetes Mellitus / Diabetic Ketoacidosis |
Phase
II completed |
| Istaroxime^ |
Acute Heart Failure |
Phase
II completed |
| Gimatecan^ |
Solid tumors (gyn. cancers) |
Phase
II completed |
| |
| ^ License-out opportunities |
| 1 Co-developed with Medicines for Malaria Venture (CH) |
| 2 Property of sigma-tau Pharmaceuticals Inc. |
| 3 In collaboration with Walter Reed Army Institute of Research (USA) |
| 4 In-licensed from Gentium S.p.A. (I) for US market |
| 5 Worldwide rights to Defiante Farmaceutica SA (P) with the exception of US/China/Japan |
| 6 Property of sigma-tau Research Switzerland S.A. (CH) |
| 7 Co-developed with GP-Pharm (E) |
8 Property of Metheresis Translational Research S.A.
and developed by sigma-tau Research Switzerland S.A. (CH) |
| 9 Property of Rostaquo S.p.A. (I) |
| 10 Property of Defiante Farmaceutica SA (P) |
| |
Favouring
Excellence
SCIENTIFIC
